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Abstract
Protein-protein interactions forming dominant signalling events are providing ever-growing platforms for the development
of novel Biologic tools for controlling cell growth. Casein Kinase 1 a (CK1a) forms a genetic and physical interaction with the
murine double minute chromosome 2 (MDM2) oncoprotein resulting in degradation of the p53 tumour suppressor.
Pharmacological inhibition of CK1 increases p53 protein level and induces cell death, whilst small interfering RNA-mediated
depletion of CK1a stabilizes p53 and induces growth arrest. We mapped the dominant protein-protein interface that
stabilizes the MDM2 and CK1a complex in order to determine whether a peptide derived from the core CK1a-MDM2
interface form novel Biologics that can be used to probe the contribution of the CK1-MDM2 protein-protein interaction to
p53 activation and cell viability. Overlapping peptides derived from CK1a were screened for dominant MDM2 binding sites
using (i) ELISA with recombinant MDM2; (ii) cell lysate pull-down towards endogenous MDM2; (iii) MDM2-CK1a complex-
based competition ELISA; and (iv) MDM2-mediated ubiquitination. One dominant peptide, peptide 35 was bioactive in all
four assays and its transfection induced cell death/growth arrest in a p53-independent manner. Ectopic expression of flag-
tagged peptide 35 induced a novel ubiquitin and NEDD8 modification of CK1a, providing one of the first examples whereby
NEDDylation of a protein kinase can be induced. These data identify an MDM2 binding motif in CK1a which when isolated
as a small peptide can (i) function as a dominant negative inhibitor of the CK1a-MDM2 interface, (ii) be used as a tool to
study NEDDylation of CK1a, and (iii) reduce cell growth. Further, this approach provides a technological blueprint,
complementing siRNA and chemical biology approaches, by exploiting protein-protein interactions in order to develop
Biologics to manipulate novel types of signalling pathways such as cross-talk between NEDDylation, protein kinase
signalling, and cell survival.
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Introduction
CK1 human isoforms - a, c1, c2, c3, d and e - represent a
unique group within the superfamily of serine/threonine specific
protein kinases that function as monomeric and constitutively
active enzymes [1,2]. They differ significantly in the length and
primary structure of their C-terminal non-catalytic domain which
is an extended tail in the case of d/e as opposed to a which has a
limited C-terminal domain, but CK1c isoforms on the other hand
vary in a longer N-terminal head [3]. Although CK1 isoforms and
associated splice variants are ubiquitously expressed, their activity
is greatly regulated via their expression levels [4], post-transla-
tional modifications by various mechanisms including subcellular
stimuli [5,6], subcellular compartmentalisation [7,8], proteolytic
cleavage of the C-terminus, auto- and de-phosphorylation of the
C-terminal regulatory domain [9]. CK1s, which were among the
first kinases described and were named after the use of casein in
the assessment of their kinase activity, have been involved in a
plethora of pathways responsible for differentiation [10], prolifer-
ation/cell cycle progression [11], chromosome segregation [12],
membrane trafficking [13,14], circadian rhythms [15], apoptosis
[16], translation initiation [17], and cell migration [18,19].
Therefore CK1 deregulation has been linked to neurodegenerative
diseases like Alzheimer’s, sleeping disorders and proliferative
diseases such as cancer. Several CK1 specific inhibitors have been
described, among them D4476 (4[4-(2,3-dihydro-benzo[1,4]-
dioxin-6-yl)-5-pyridin-2-yl-1-H-imidazol-2-yl]benzamidine) which
is an ATP-competitive inhibitor active on CK1 in the nanomolar
range in vitro [20,21]. In addition, a novel stimulator of CK1a has
been identified named pyrvinium that opens the door to
pharmacological induction of CK1a flux in cells [22,23].
The transcription factor p53 is a tumour suppressor protein that
prevents propagation of damaged cells with potentially cancer-
prone mutations by triggering cell cycle arrest, repair mechanisms,
apoptosis, and immune system engagement [24,25,26]. Mutation-
al inactivation of p53 leads to genome instability, immune system
evasion, and metabolic stress in human tumours that can mediate
drug resistance. Nonetheless, some p53 mutant tumours can allow
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sensitization to specific therapeutic interventions [27]. Under
normal conditions, p53 is negatively regulated by the murine
double minute chromosome 2 (MDM2) protein which results in
both ubiquitination and subsequent degradation of p53 by the
proteasome as well as direct repression of p53 transcription activity
[28]. The mechanism is controlled through the ability of p53 to
transcriptionally activate the mdm2 gene in a negative feedback
loop [29,30]. MDM2 has been divided into several domains [31]:
a regulatory lid; an N-terminal allosteric hydrophobic pocket; a
nuclear localization signal and a nuclear export signal; an
intrinsically disordered acidic domain that drives a large number
of MDM2 interactions; a C-terminal RING domain; and an ATP-
binding motif. Ubiquitin ligase function of MDM2 toward p53 has
been shown to involve a two-site docking model: occupation of the
N-terminal hydrophobic pocket of MDM2 by a motif within the
N-terminus of p53 induces docking between the acidic domain of
MDM2 and an ubiquitin-signal in the DNA-binding domain of
p53 [31].
The dynamic interaction between p53 and MDM2 relies on
integration of post-translational modifications driven by multiple
signalling pathways [26,32]. Phosphorylation of both p53 and
MDM2 can be regulated by the same kinase, Casein Kinase 1
(CK1) isoforms - a, d, and e - which has been shown to
phosphorylate p53 after transforming growth factor beta [33],
some DNA damage signals [34] or virus infection [6], which frees
p53 from MDM2 [35]. CK1 has also been shown, in proliferating
conditions, to phosphorylate residues within the acidic domain of
MDM2, favouring MDM2 functions toward p53 [36,37,38]. CK1
would thus have a dual role, possessing some proto-oncogene
functions on one hand but it could switch towards a tumour
suppressor function, depending on recruitment into specific
complexes under different conditions.
Disruption of the p53-MDM2 complex using chemicals like
Nutlin-3 that destabilise the protein-protein interface between
MDM2 and p53 is a fundamental pharmacologic approach for
p53 activation as a cancer therapeutic. Our previous data
indicated that CK1 and MDM2 form a stable protein-protein
complex that regulates the steady-state levels of the p53 tumour
suppressor protein in cancer cell lines [16]. The observation that a
small molecule inhibitor of CK1 can act like the MDM2 binding
molecule Nutlin to stabilize p53 and induce cell death, also
suggests that CK1 forms an attractive target for anti-cancer
therapeutics. In this study, we aimed to determine whether
disruption of the protein-protein interaction between MDM2 and
CK1a give rise to similar and/or novel biological insights
compared to the use of siRNA or small molecule pharmacological
kinase inhibitors that either deplete CK1 protein or ‘‘inhibit’’
kinase activity but do not lead to protein kinase degradation,
respectively. This concept is relatively important to begin to
address since there is growing interest in ‘‘drugging’’ protein-
protein interactions as therapeutic strategies in disease like cancer
[39,40]. We define a dominant functional motif in CK1a that
forms the core protein-protein interface between MDM2 and
CK1a using a functional in vitro/in vivo peptide-binding screen.
This research led to the identification of a specific peptide derived
from the ‘‘base’’ of CK1a capable of de-stabilizing the MDM2-
CK1a complex, and inducing p53-independent cell death. This
approach highlights how protein-protein interfaces can be
exploited to develop novel Biologics, which can be used to dissect
signal transduction mechanisms and provide leads for novel
therapeutics to target specific MDM2 protein-protein interactions
in cancer cells [41].
Results
CK1a Protein Depletion or Pharmacological Kinase
Inhibition Activates p53 and Induces its Nuclear
Relocalisation Revealing a CK1a-MDM2 Complex
CK1a was recently identified as a repressor of the p53 pathway
in A375 cells; siRNA against CK1a or D4476, a specific ATP-
competitive kinase inhibitor against CK1, resulted in accumula-
tion of the p53 protein [16], as previously reported after IC261
treatment [42]. These results were reproduced in HCT116
colorectal cancer cells (Figure 1A) and also in A375 cancer cells
(Figure S1) with isoform-specific siRNA against CK1a (CSNK1A1
gene), which reduced specifically the levels of CK1a (Figure 1A
lanes 4&8 vs. 3? Figure S1). In p53 wt cells (Figure 1A lanes 1–4),
the down-regulation of CK1a protein triggered p53, MDM2 and
p21 increases. The proposed mechanism for these changes in p53/
MDM2 pathway is a disruption between MDM2 and p53 binding
after CK1a depletion, leading to an increase of p53 protein along
with an increase of p53-inducible gene products MDM2 and p21.
Indeed these observations matched the effects of Nutlin-3a
treatment [16] and are consistent with the ability of CK1 to
induce MDM2 phosphorylation within its acidic domain, which is
believed to positively control MDM2 activities toward p53 [38].
Nuclear localization is critical for wild type p53 transactivation
function. Here, we examined the effect of CK1 inhibition on the
subcellular localization of p53 in A375 cell line in which p53 is
normally mainly sequestered in the cytoplasm in unstressed
conditions (Figure 1B lanes 1–4). D4476 treatment triggered an
increase of nuclear p53 protein level (Figure 1B lanes 3 vs. 7;
Figure S2), while a slighter increase in cytosolic p53 protein level
was observed (Figure 1B lanes 5 vs. 1; Figure S2).
Expression of CK1 isoforms were also assessed and interestingly
after D4476 treatment, CK1a, d and e protein levels increased
significantly (Figure 1B), which highlights the different effects that
siRNA or a small molecule pharmacological inhibitor can have on
target protein levels in cells. That is, it cannot be assumed that
kinase inhibition is genetically identical to removing a protein
using siRNA or gene knockout approaches. As a control, CK1d
and e levels didn’t increase after treating cells with CK1a targeted
siRNA (Figure S1). Such increases of CK1d and e were previously
observed after IC261 treatment [42], another ATP-binding pocket
CK1 inhibitor [43]. These increases were explained as a response
to compensate the inhibition of casein kinase 1 isoforms [44]. After
D4476 treatment, CK1a protein cytosolic level increased by about
3-fold, d by 6-fold and e by 2-fold (Figure S2), which could reflect
the different inhibition sensitivity of the distinct isoforms by
D4476. But it was previously shown in A375 cells that p53,
MDM2 and p21 protein level changes couldn’t be attributed to
other isoforms as CK1d siRNA for example didn’t induce these
protein level increases [16].
Two standard approaches are used to dissect a signalling
pathway; either targeting components at the mRNA level with
specific siRNA or at the protein level with small molecule
inhibitors. There is a third way to manipulate signalling complex
like CK1a-MDM2, by targeting the interface to discover a new
biologic tool whose effects on cell death/growth arrest abilities can
be investigated (Figure 1C). Targeting protein-protein interactions
is growing as a dominant approach in therapeutics and in this
manuscript we develop a biologic tool to this interface to compare
siRNA and small molecule inhibitors in order to develop new
insights into signalling and novel therapeutic approaches for
targeting MDM2 and CK1 in cancer (Figure 1C).
A Novel MDM2 Binding Peptide Induces Cell Death
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CK1a Transcript Variant 2 Forms a Stable Multi-protein
Complex with MDM2 in Cells
MDM2 has been shown previously to co-immunoprecipitate
with the CK1a isoform [16]. In order to assess if this was true
using different MDM2 antibodies, we performed co-immunopre-
cipitations with these antibodies from the same lysate. The
MDM2-CK1a complex was isolated with each of the antibodies,
notably the 2A10 monoclonal antibody (Figure 2A upper panel
esp. lane 5) that also showed the greatest quantity of immunopre-
cipitated MDM2 (Figure 2A lower panel). In the same experiment
(Figure S3A & B), even though CK1a was co-immunoprecipitated
with MDM2 in A375 cells, CK1d and e failed to be detected even
though they were previously shown to interact with MDM2 [45].
The endogenous MDM2-CK1a complex was also captured by
immunoprecipitation using CK1a antibody (Figure 2B lane 15).
With MDM2 immunoprecipitations, only the lower and also more
abundant band of the two input bands observed using the CK1a
antibody is clearly co-immunoprecipitated, which could possibly
reflect the lack of sensitivity of the assay (Figure 2A esp. lane 5,
Figure 2B lane 13, upper panels). This observation suggested that
the dominant of the two potential ‘‘isoforms’’ of CK1a was
interacting with MDM2 and led us to further investigate the
nature of these two bands observed by CK1a immunoblotting in
cell lysates (Figure 1A lanes 1 & 5; Figure 2B lane 11) in order to
further refine the complexity of the various isoforms of CK1. Both
bands appear to represent CK1a, since CK1a siRNA decreased
each of them (Figure 1A lane 8 vs. 7 & 4 vs. 3).
From our available knowledge [8,46,47] on the CK1a gene in
humans, there are two known transcript variants resulting from
Figure 1. Effects of CK1a depletion or inhibition on the stability and subcellular localisation of the p53 protein. (A) HCT116 wt (lanes
1–4) and p532/2 (lanes 5–8) cells were transfected with control (40 nM; lanes 3&7) or with CK1a-specific siRNA (40 nM; lanes 4&8) for 96 hours. A
Mock transfected control (lanes 2&6) and an untreated control (DMEM only; lanes 1&5) were included. Cell lysates were analysed by Western blotting
with antibodies targeting the indicated proteins. (B) A375 cells were transfected with 40 mM final concentration of the CK1 inhibitor D4476 for 72
hours (lanes 5–8). A Mock/DMSO control (lanes 1–4) was included. Cells were fractionated into four subcellular compartments: cytosol, membranes
and membrane organelles, nucleic proteins, and cytoskeletal components. Subcellular fractions were immunoblotted with antibodies targeting the
indicated proteins. (C) Strategies for manipulating signalling complexes under normal growing conditions, CK1a interacts with MDM2, which
promotes its binding to p53 and leads to p53 ubiquitination and degradation but also to inhibition of transactivation of p53 targets, p21 for example.
After genetic depletion of CK1a by siRNA, the loss of the bioactive complex between MDM2 and CK1a could explain the stabilization of p53.
Alternatively, the MDM2-CK1a complex might be inactivated for example by using an ATP-competitive inhibitor D4476 which induced p53
accumulation and cell death. The approach developed here was to target the dominant sit of protein-protein interaction between the MDM2-CK1a
complex to identify a potentially bioactive CK1a interface peptide that would form a new specific biologic tool to manipulate cancer cell growth.
doi:10.1371/journal.pone.0043391.g001
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Figure 2. MDM2 preferentially binds CK1a splice variant 2. (A) MDM2 was immunoprecipitated from A375 cell lysate using a panel of MDM2
antibodies: 2A10, 2A9, 4B2, 3G5 and SMP14. Co-immunoprecipitation was performed and proteins in the immune precipitate were analysed by
Western blotting with anti-CK1a and antibody targeting the immunoprecipitated MDM2 protein (1:1 mix of 2A10 and 4B2). A ‘‘no antibody’’ control
(No Ab) was included. The flow-through (FT) and the eluate (E) were analysed along with the pre-cleared lysate (input). (B) MDM2 or CK1a was
immunoprecipitated from cell lysates transfected (lanes 16–19) or not (lanes 11–15) with untagged MDM2. Co-immunoprecipitation was performed
and proteins in the immune precipitate were quantified by Western blotting with anti-CK1a and anti-MDM2 4B2 antibodies. Various
immunoprecipitation controls were included (lane 2–5 and 7–10) and inputs for each lysate (lanes 1 & 6; input 1: non-transfected cells, input 2:
MDM2 transfected cells) (C) Normalisation of GST-CK1a splice variant 1 and 2 proteins (used in (D) and (E)) was performed by ELISA using a CK1a
antibody. (D) Purified GST-CK1a splice variant 1 or 2 or GST alone were coated on the ELISA plate and a titration of purified untagged MDM2 was
added in the mobile phase. Antibody against MDM2 and the appropriate secondary antibody were used to quantify the binding using ECL (relative
light units (RLU)). (E) Purified GST-cleaved MDM2 or control buffer alone (‘‘c sp1’’ and ‘‘c sp2’’) were coated on the ELISA plate and a titration of
purified GST-CK1a splice variant 1 or 2 added. Antibody against CK1a and the appropriate secondary antibody were used to quantify the binding
using ECL (in relative light units (RLU)). The figure is representative of two independent experiments in which each data point was assessed in
triplicate. (F) A375 cells were transfected with either empty vector (lane 1) or the One-STReP-tagged CK1a splice variants 1 (lane 2) and 2 (lane 3).
After gentle lysis, the lysates were incubated with STReP-Tactin beads and bound proteins eluted by heating at 85uC in SDS/DTT sample buffer.
Protein levels from the lysates (lanes 1–3) and the matching eluates (lanes 4–6) were analyzed by Western blotting with antibodies targeting the
indicated proteins.
doi:10.1371/journal.pone.0043391.g002
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alternative splicing of CSNK1A1. They are CK1a transcript/splice
variant 1 (or sp1; 365 amino acids) with a predicted size of 42 kDa
that would correspond to the upper band, and CK1a sp2 (exon 5
is spliced out) with a size of 39 kDa matching the lower band
(Figure 3A). To evaluate whether these two bands are likely to be
CK1a sp1 and 2, both CK1a splice variants were cloned and
expressed as untagged proteins using an in vitro transcription/
translation kit (Figure S4 lanes 2&3 respectively). Indeed, the size
of each in vitro translated CK1a matched one band of CK1a
transcript variants from A375 lysate (Figure S4 lane 4).
Additionally, when MDM2 was transfected into A375 cells, the
quantity of CK1a sp2 being co-immunoprecipitated with MDM2
didn’t increase even though the amount of MDM2 immunoprecip-
itated was considerably enhanced (Figure 2B lane 17 vs. 13). CK1a
sp1 was however pulled down with increased level of exogenous
MDM2. Curiously, the amount of MDM2 being co-immunopre-
cipitated with same level of CK1a was increased when MDM2 was
transfected (Figure 2B lane 15 vs. 19), highlighting the possible
presence of different cellular pools of MDM2-CK1a complex.
As a first step to test if there is an intrinsic difference in the
binding between MDM2 and CK1a splice variants, ELISA
experiments were performed using titrations of bacterially
expressed and purified MDM2 and GST-tagged CK1a sp1 and
2 whose amounts were carefully normalised by ELISA (Figure 2C).
Binding of MDM2 to CK1a sp1 and 2 in the solid-phase was
observed implying a direct association between both proteins, but
no striking difference was seen in the relative values (Figure 2D).
However, in the inverse ELISA, CK1a sp2 displayed greater
binding to MDM2 in the solid-phase compared to sp1 (Figure 2E).
A similar trend was detected by pull-down of strep-tagged CK1a
sp1 and 2 transfected into A375 cells; only sp2 exhibited elevated
binding to endogenous MDM2 (Figure 2F lane 6 vs. 4&5).
Therefore, since CK1a sp2 seems to be the major splice variant
present in cells and in addition displays greater intrinsic binding to
MDM2 in vitro as well as in vivo, subsequent experiments mainly
used transcript variant 2.
Fine-mapping the CK1a-MDM2 Protein Interface
The use of Biologic tools, such as aptamers, peptide mimetics or
nanobodies provides novel approaches to dissect signalling path-
ways. We therefore aimed to develop peptides representing the
MDM2-CK1a interface in order to uncover potentially novel
concepts in cell growth control and to develop novel therapeutic
leads for targeting this complex in cancer cells. In order to define the
dominant contacts in the CK1a-MDM2 interface, a CK1a
overlapping peptide library was synthesised and used in a series of
competitive and direct binding experiments. These peptides were 15
amino acids long with a 5 amino acid overlap on each side, and
featured an N-terminal biotin tag separated from the peptide
sequence by an SGSG spacer (Figure 3B). Special care was taken in
the design of the spliced region peptides which had a greater degree
of overlap (peptides 15–22) and some additional peptides were
designed to span the spliced region (peptides 41–42) that is present
only in CK1a sp1 (Figure 3A). The spliced region does not appear in
any otherCK1 isoforms and since only the 3D structure ofCK1dbut
not a has been determined, an automated protein structure
homology modelling server SWISS-Model was used to determine
the most probable CK1a 3D structures [48,49] (Figure 3C). This
region is interesting as it appears to have a tendency for disorder
(Figure 3D) but to a lesser extent than the CK1a N-terminal head
and C-terminal regulatory tail (Figure 3A & D).
In vivo pull-down experiments from A375 cell lysate were
performed with each of the CK1a peptides immobilised on
streptavidin-agarose beads (Figure 4A & B). Peptides 2, 28 and 35
captured the most endogenous MDM2 from the lysate. They differ
in their abilities to associate with cellular MDM2, highlighting the
specificity of the binding assay; peptide 35 captures MDM2 far
better than peptides 2 and 28 (Figure 4B). In order to corroborate
these results in an independent assay, recombinant MDM2
binding to CK1a peptides was evaluated by ELISA (Figure 4A
& C) and revealed a similar pattern. A summary of MDM2
binding to CK1a peptides by either ELISA and in vivo pull-down is
displayed in Table 1. Interestingly, peptide 2 which showed
significant binding to MDM2 contains a potential p53 BOX-I-like
motif. Interaction between the p53-BOX-I domain and the N-
terminus/hydrophobic pocket of MDM2 was shown to promote
conformational changes in MDM2 that stabilize acidic domain
interactions with an ubiquitination signal in the DNA binding
domain (BOX-V) of the p53 tetramer [31]. Therefore, peptides 2,
28 and 35 that bound specifically to cellular MDM2, as well as
recombinant MDM2, were brought forward for MDM2-CK1a
interface study.
Key CK1a Peptides Disrupt the CK1a-MDM2 Complex
and Inhibit MDM2’s E3 Ligase Activity
To assess if the CK1a peptides which displayed binding affinity
to MDM2 by ELISA and in vivo pull-down were able to disrupt the
binding between CK1a and MDM2, peptide competition ELISAs
were performed on the same basis as direct binding assays
(Figure 2D) but with an additional peptide-MDM2 pre-incubation
step. A titration of the panel of selected peptides was pre-incubated
with MDM2 protein before addition to CK1a sp2 coated on the
plate. Peptide 1 was used as a control since it did not bind to
MDM2 in ELISA and pull-down experiments (Figure 4B & C).
Only peptides 28 and 35, but not peptides 1 or 2, were able to
decrease the binding of MDM2 to CK1a in a dose-dependent
manner (Figure 5A). A quantitative summary of these results is
displayed in Table 1. With the purpose of evaluating these data,
binding between CK1a and MDM2 was assessed after pre-
incubation with reference peptides known to bind different regions
of MDM2: BOX-I, derived from the N-terminus of p53 which was
shown to bind to the hydrophobic pocket of MDM2; BOX-V from
the DNA binding domain of p53 that was shown to bind the acidic
domain of MDM2 [31]. Pyrvinium was also included, which is an
appealing molecule recently shown to bind selectively to CK1a
and to allosterically activate CK1a in vitro [23]. The binding of the
BOX-I peptide, like peptide 2, did not affect the CK1a-MDM2
complex at all (Figure 5B). On the other hand, BOX-V competed
the binding in a similar manner to peptide 35 or 28 (Figure 5A &
B). Lastly, pyrvinium increased the binding between CK1a and
MDM2 (Figure 5B). Interestingly, pyrvinium was previously
shown to selectively potentiate CK1a kinase activity [23] which
highlighted the ability of pyrvinium as a small molecule tool for
perhaps stimulating CK1a pathways.
Since two CK1a peptides were able to effectively block the
CK1a-MDM2 interaction by binding to MDM2, we wanted to
determine whether these peptides would also be able to inhibit
MDM2’s E3 ubiquitin ligase activity. To perform this test, we used
a well-established assay based on in vitro ubiquitination of p53 by
MDM2 [31,50]. Without MDM2, p53 appeared as a single band
(Figure 6 lane ‘‘-E3’’) which was replaced by an ubiquitinated
adducts ladder in the presence of MDM2 (Figure 6 lane ‘‘D’’).
CK1a peptides that were brought to light in the previous CK1a-
MDM2 binding assays, also had the ability to inhibit p53
ubiquitination by MDM2 in a similar manner as has previously
been reported for BOX-V peptide [31]. Peptide 2 almost
completely inhibited p53 ubiquitination at 50 mM and peptide
28 was also inhibitory but to a lesser extent, while peptide 35
A Novel MDM2 Binding Peptide Induces Cell Death
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Figure 3. Features of CK1a transcript variants 1 and 2 and design of overlapping peptides. (A) Schematic representation of CK1a splice
variant 1/2 highlighting the main features of CK1a including the nuclear localisation sequences (NLS) and the serine/threonine kinase catalytic
domain. The ‘‘L’’ insertion is present in CK1a sp1 (aligning with CK1aLS from Danio rerio) but spliced in CK1a sp2 (CK1aS). The ‘‘S’’ insertion can be
spliced in zebrafish, but the existence of a corresponding splice variant remains unknown in humans. (B) Overlapping peptides that were 15-amino
acids long were designed spanning the entire length of the CK1a protein, featuring a 5-amino acid overlap at each extremity, with an N-terminal
biotin tag and SGSG spacer. The light-grey amino acid sequences are specific to CK1a splice variant 1. Therefore peptides 15 to 22 with tighter
overlap are splice variant 1 specific, and dark-grey peptides 41–42 are splice variant 2 specific. (C) Secondary structure cartoons of CK1a (amino acid
10-335 for sp1 and 10-307 for sp2) were generated using SWISS-MODEL which is an automated protein structure homology-modelling server. It
predicted the three dimensional structures of CK1a sequences based on their similarities with the experimentally determined crystal structure of
CK1d protein (PDB ID: 1CKI_A). In white is shown the region where the alternatively spliced sequence of CK1a transcript variant 1 is inserted. N-, C-
terminus and the position of the ATP-binding cleft are pointed out by arrows on the cartoon structure. (D) Disorder probability analysis of the CK1a
protein sequence was determined using DISOPRED2 with a false positive rate of 5% (filter threshold). The filter curve corresponds to the output from
DISOPRED2, and the output curve from DISOPREDsvm indicates shorter, low confidence predictions of disorder (http://bioinf.cs.ucl.ac.uk/disopred/).
doi:10.1371/journal.pone.0043391.g003
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inhibited MDM2 E3 ligase activity from 2.3 mM (Figure 6). The
comparative significance of the effects of each peptide in the
ubiquitination assay is summarized in Table 1.
Using the relative bioactivity of each peptide within the
described assays assessing the CK1a-MDM2 complex (see
Table 1), the significance of each peptide was assessed by giving
an overall mark. Thus, peptide 35 is underlined as having the best
score for being implicated in disrupting MDM2-CK1a binding.
The peptide 35 motif is well exposed on the ‘‘bottom’’ surface of
CK1 (Figure 7) and was chosen as the best candidate interface
peptide between the MDM2 oncoprotein and the kinase. Peptide
2 is a prominence located just above the ATP-binding pocket of
CK1 (Figure 7) and was excluded from the study since it was not
bioactive in all four assays (i) ELISA with recombinant MDM2; (ii)
cell lysate pull-down towards endogenous MDM2; (iii) MDM2-
CK1a protein-protein interaction complex-based competition
ELISA; and (iv) MDM2-mediated ubiquitination.
Figure 4. MDM2 binds to a dominant small motif within CK1a. (A) Biotinylated CK1a peptides were used to generate streptavidin-based
peptide aptamer affinity columns for cell lysate MDM2 interaction assessment (B), or were coupled to streptavidin coated plates for direct ELISA
binding assay (C). (B) Pre-cleared A375 lysate was applied to peptide aptamer affinity columns. A DMSO control was included. Eluates from the
peptide aptamer affinity columns were analyzed on 10% gels and MDM2 binding was analyzed on immunoblots probed with anti-MDM2.
Quantification of bound MDM2 protein level was performed using Scion Image software. (C) Mapping of MDM2 binding to overlapping CK1a
peptides by ELISA. Overlapping CK1a peptides were coupled to streptavidin coated plates. Purified GST-cleaved MDM2 was added to each peptide
and antibody against MDM2 and the appropriate secondary antibody were used to quantify the binding using ECL (in relative light units (RLU)). A
DMSO control was included and values were normalised against the BSA background. The data are representative of three independent experiments
in which each data point was assessed in triplicate.
doi:10.1371/journal.pone.0043391.g004
Table 1. Summary of the significance of selected CK1a
peptides in the linear binding peptide interface of CK1a-
MDM2 complex.
CK1 peptide number 1 2 28 35
MDM2 binding to CK1
peptides by ELISA
– ++ + ++
MDM2 from lysate binding
to CK1 peptide columns
– + + ++
Peptide competition of
CK1a-MDM2 binding
– – + ++
Peptide competition of p53
ubiquitination by MDM2
– ++ + +++
Score of peptide/9 0 5 4 9
doi:10.1371/journal.pone.0043391.t001
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Figure 5. Key CK1a peptides can inhibit CK1a-MDM2 complex formation in vitro. GST-CK1a splice variant 2 was coated on ELISA plates.
Purified GST-cleaved MDM2 was pre-incubated (with the exception of pyrvinium which was not pre-incubated but added to the plate at the same
time as MDM2) with (A) CK1a peptides, namely peptides 1, 2, 28 or 35 (the data are representative of two independent experiments), or (B) MDM2
ligands (BOX-I and BOX-V) and CK1 stimulatory ligand pyrvinium, and then added to the plate. DMSO controls and a non-binding peptide (peptide 1)
were included. MDM2 binding to CK1a was quantified using an antibody specific for MDM2 and an appropriate peroxidise-conjugated secondary
antibody, by enhanced chemiluminescence (ECL) as relative light units (RLU). Each data point was assessed in triplicate.
doi:10.1371/journal.pone.0043391.g005
Figure 6. MDM2 interacting peptides derived from the sequence of CK1a can inhibit the E3 ubiquitin ligase function of MDM2
in vitro. In a peptide competition ubiquitination assay, untagged p53 protein purified from Sf9 insect cells was incubated with ubiquitin, UBE1 (E1),
UbcH5a (E2) and ATP in the presence of full-length MDM2 pre-incubated with selected CK1a peptide 1, 2, 28 or 35, or BOX-I/2V) MDM2 ligands.
Reactions were performed for 5 min at 37uC. Samples were analysed by immunoblotting with an anti-p53 antibody. A control with no MDM2 (‘‘-E3’’,
peptide 2+ p53 only) and a DMSO control (‘‘D’’) were included.
doi:10.1371/journal.pone.0043391.g006
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The Bioactive Peptide 35 Triggers Changes in Cell
Viability and a G0-G1 Growth Arrest in a p53
Independent Manner
In a manner similar to CK1a siRNA and D4476, we
investigated the possibility that CK1a peptides that competed
with full-length CK1a for binding to MDM2 could also trigger the
p53 pathway in A375 cancer cell line. To evaluate this hypothesis,
the highly scoring peptide 35 (Table 1) was transfected into cells
using Nucleofectin transfection reagent and electroporation. Using
this approach, peptide 35 caused no striking increase in p53 levels
(Figure 8A & 9A), but its downstream target p21 increased
significantly compared to DMSO control (Figure 8A). In the same
experiment, protein levels from cells transfected with higher
concentrations of peptide 35 could not be measured accurately as
cells were mostly all dead (Figure 8B). A lower titration of peptide
35 was therefore used and even at concentrations as low as 5 mM a
growth inhibitory effect was seen on the cells, that were floating
and non-viable at higher concentrations (Figure 8B). This low mM
bioactivity of peptide 35 in cells is suggestive of a potent Biologic
tool. Indeed increasing concentration of peptide 35 triggered a
reduction of total cell number compared to the control alongside
an increase in the proportion of non-viable cells (Figure 8C). In
order to characterise this cell viability effect, FACS analysis was
performed based on propidium iodide staining of the cell DNA, 18
hours after transfection of low levels of peptide 35. At a 10 mM
peptide 35 concentration in A375 cells, a significant G0–G1
growth arrest was observed with an 11% increase compared to the
DMSO control (Figure 8D).
Since p53 protein was seen to only increase slightly at higher
peptide 35 concentrations, the possibility that the observed growth
arrest would be p53-independent was assessed by using HCT116
wt and p532/2 cells (Figure 9). Indeed, the decrease in cell
viability after peptide 35 transfection was observed with a similar
intensity in both HCT116 cell lines (Figure 9B & C). FACS
profiles also showed an increasing G0-G1 cell population in the
presence of increasing peptide concentrations (Figure 9D). An
additional 1.7-fold increase of apoptotic sub-G1 population was
observed in p532/2 cells, which could be explained by previously
suggested anti-apoptotic role of p53 [51]. No p53 increase but only
a p21 protein level increase was observed after transfection of
HCT116 wt (Figure 9A). Possibly linked to the absence of p53, no
increase of p21 was observed in p532/2 cells, which would
suggest that the observed G0-G1growth arrest was not linked to
the p21 protein level increase (Figure 9A & D).
Bioactive Peptide 35 Induces Ubiquitination and
NEDDylation-like Modification of the Splice Variant 2
CK1a
Overall, peptide transfection did not trigger a significant p53
protein level increase although it induced noteworthy growth
Figure 7. Analysis of MDM2 binding motifs within the overall three dimensional structural homology model of CK1a. Space-filling
representation of CK1a sp2 generated using SWISS-MODEL (see figure 3 for details), is displayed at different angles. Secondary structure image of the
primary space-filling molecule is shown in the bottom left corner. Regions highlighted in various colours correspond to CK1a peptides 2, 28 and 35.
doi:10.1371/journal.pone.0043391.g007
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arrest and cell death from as little as 5 mM transfected-peptide
concentrations, in a p53-independent manner (Figure 8 & 9 &
10B). Potentially novel interactions/modifications of CK1a in vivo
after peptide 35 disruption of the CK1a-MDM2 complex might
give new insights into cell death signalling events. To address this,
we cloned peptide 35 in frame with an N-terminal FLAG tag.
Ubiquitin and NEDDylation-like modifications were assessed after
FLAG-tagged peptide 35 co-transfection with STrEP-tagged
CK1a sp1 or 2 in H1299 cells. This experimental approach
revealed significant increase of these post-translational modifica-
tions for CK1a splice variant 2 but not sp1 (Figure 10A),
emphasizing novel interactions/modifications of CK1a following
its release from the E3 ligase MDM2. These data highlight how an
approach to develop a Biologic tool based on a protein-protein
interface can give rise to novel information about cellular
signalling; in this case we have identified a peptide that can
induce growth arrest and reduce cell viability in a p53-
independent manner, and co-ordinately induce ubiquitination
and novel NEDDylation signals to CK1a that might explain in
part alterations in growth responses. The further optimisation of
peptide 35 as an MDM2-targeting lead that co-ordinates
NEDDylation might provide a novel pharmacological tool to test
as an anti-cancer therapeutic.
Figure 8. The CK1a peptide derived from its dominant MDM2 binding site triggers G0-G1 arrest and cell death in A375 cells. CK1a
peptide 35 was transfected into A375 cells using Nucleofectin reagent and Nucleofector device II. A DMSO control was included. (A) Protein levels
were assessed 18 hours after peptide transfection by Western blotting. (B) Images of cells were captured 16 hours after transfection. (C) The number
of non-viable cells was counted after treatment using Trypan Blue. Total cells are shown in percent relative to the DMSO control and percent of non-
viable cells are expressed relative to each respective total cell count. (D) After treatment, the cells were harvested then fixed in ethanol followed by
staining with propidium iodide. DNA content was determined by FACS and analyzed with FlowJo7 software.
doi:10.1371/journal.pone.0043391.g008
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Figure 9. CK1a peptide derived from its dominant MDM2 binding site triggers G0-G1 arrest and cell death in a p53-independent
manner. CK1a peptide 35 was transfected into HCT116 cells using Nucleofectin reagent and Nucleofector device II. A DMSO control was included.
(A) Protein levels were assessed 18 hours after peptide transfection by Western blotting. (B) Images of cells were captured 16 hours after transfection.
(C) The number of non-viable cells was counted after treatment using Trypan Blue. The percentage of non-viable cells is expressed relative to each
respective total cell count. (D) After treatment, the cells were harvested then fixed in ethanol followed by staining with propidium iodide. DNA
content was determined by FACS and analyzed with FlowJo7 software.
doi:10.1371/journal.pone.0043391.g009
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Discussion
MDM2 is a known inhibitor of p53, but MDM2 also has over
one-hundred other interacting proteins whose link to p53
inhibition and cell growth controls are not well defined; nor is
there an annotation of which of these over hundred MDM2
interactors are dominant or less significant which would clarify
their importance as therapeutic targets in cancer [27]. We have
previously evaluated the CK1 family as established MDM2
interactors, to determine whether they are part of the same
genetic p53-inhibitory pathway as MDM2. Previous published
data indicated that blocking MDM2 with Nutlin-3a or depleting/
inhibiting CK1a generated the same genetic effects: an increase of
p53, MDM2 and p21 protein levels ([16], Figure 1A). Thus we
propose that of the many MDM2 binding proteins, CK1a is a
dominant MDM2 interacting protein. Sub-cellular fractionation
experiments showed that CK1 inhibition induces significantly p53
nuclear levels thus allowing its transcriptional activity (Figure 1B).
We previously proposed a molecular mechanism by which the
p53-MDM2 association is regulated through the modulation of
recruitment of protein kinases such as CK1, thus influencing CK1
substrate selectivity. The present study investigated the interaction
mechanism between CK1a and MDM2 protein in order to further
our understanding of the role of CK1a in regulating p53-MDM2
signal transduction pathways and to investigate whether novel
domains in CK1a can be identified (forming Biologics tools) to
stimulate further research (Figure 1C).
The genetic cooperation of CK1a and MDM2 as an ‘‘onco-
complex’’ that inhibits p53 and has proliferating associated
functions was tested by dissecting the protein-protein interaction
interface between CK1a and MDM2. Two key interfaces are
already identified in MDM2 that bind CK1: (i) phosphorylation
sites in the acidic domain of MDM2 that activate it [38]; and (ii) a
DSG motif (also known as phosphodegron) surrounded by
numerous close potential phosphorylation sites, some of which
could be phosphorylated by CK1 in a primed or non-primed
manner [52]. Phosphorylation of this degron leads to recognition
by b-TrCP E3 ligase, resulting in MDM2 degradation [45].
Figure 10. Outline of pharmacological manipulation of CK1 functions and its effects on p53 signalling pathway, cell viability, and
CK1a post-translational modifications. (A) H1299 cells were transfected with STReP-tagged CK1a sp1 or 2, FLAG-tagged peptide 35 and His-
Ubiquitin or His-Nedd8, using Attractene. Eighteen hours after transfection cells were treated with 50 mM MG132 for 4 hours. Whole cell lysates were
analysed for transfected CK1a levels, and His-ubiquitin/NEDD8 conjugates were purified by metal affinity chromatography and analyzed by 4%–12%
NuPAGE/immunoblots with an anti-CK1a antibody. Changes highlighted were representative of two independent experiments. (B) Three approaches
for manipulation of signal transduction pathways. Genetic depletion of CK1a using siRNA or the CK1 kinase attenuation using the ATP-competitive
inhibitor D4476 can alter the p53 response and cell viability, as indicated. The bioactive peptide from the high affinity MDM2-CK1a interface (peptide
35) highlights a novel peptide lead for disrupting signalling in cancers. All three approaches gave rise to overlapping but distinct effects on signalling.
Specific siRNA against CK1a led to p53 induction and growth arrest accompanied with slight sub-G1 increase, whereas non-specific CK1 drugs such as
D4476 mediated p53 induction and significant apoptosis. Low levels of the bioactive peptide 35 did not lead to p53 protein induction but to a
growth arrest in G0-G1 and reduced cell viability. These data suggest that peptide 35 may function in a pharmacologically novel manner compared to
the ATP-active site inhibitor or CK1a siRNA and highlights the general utility of targeting protein-protein interactions as approaches for developing
therapeutic strategies that target signalling mechanisms in cancer.
doi:10.1371/journal.pone.0043391.g010
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Mapping the interfaces between CK1a and MDM2 highlighted
specific linear peptide motifs as binding signals or interfaces CK1a
presented an N-terminal p53 BOX-I-like motif that is a canonical
MDM2 hydrophobic pocket binding site. This is relatively novel in
itself, as although a similar p53 dual-site docking ubiquitination
mechanism by MDM2 was shown to operate on the IRF-2
transcription factor [53] and cell-fate determinant NUMB [54],
only few proteins are known to possess a BOX-I motif and interact
with MDM2. Another observation from the 3D structure of CK1
is that the first MDM2-binding motif is located within a loop/b-
sheet/loop structure over the ATP-binding pocket (Figure 7).
The most remarkable interface is located close to the C-
terminus of CK1a, at the edge of the kinase domain, with peptide
35 located in the ‘‘base’’ area of the 3D structure of the kinase
(Figure 7). Peptide 35 sequence is quite conserved between CK1
isoforms [2]. We could hence infer that similarly to CK1 drugs,
peptide 35 would not only affect CK1a pathways but possibly
other CK1 isoform protein-protein interactions. However, al-
though peptide 35 sequence is conserved between CK1 isoforms,
the double mutation of two non-conserved residues within CK1e/
CK1a peptide 35 interface abolished CK1e specific interaction
with Dishevelled protein [55], highlighting that even within a
conserved region, single non-conserved residues could still drive
specific isoform interactions.
Interestingly, here peptide 35 has been shown to induce
reduction of cell viability in a p53 independent manner. We
ventured the hypothesis that freeing CK1a from its complex with
MDM2 (using small molecules or Biologics) is the key event
triggering growth arrest/cell death. While the role of CK1a as a
regulator of MDM2/p53 activity has been previously shown, new
insights into its regulation are of potential interest since CK1a it is
involved in so many pathways such as TGF-b signalling, virus
responses, and DNA-damage responses [56]. Indeed an increase in
CK1a protein levels was noticed after peptide 35 transfection;
moreover ubiquitin and NEDDylation-like post-translational
modifications of CK1a splice variant 2 are significantly increased.
This is the first time a kinase has been shown to be NEDDylated to
the best of our knowledge. These ubiquitin-like modifications
might be priming events of the tumour suppressor functions of
CK1a, when this it is freed from MDM2 interaction.
Our studies in A375/HCT116 cells suggest that CK1a can be a
proto-oncoprotein by having anti-apoptotic and proliferative
effects as its inhibition or depletion leads to p53 induction and
growth arrest or apoptosis [16]. The same conclusion was drawn
in a study showing that CK1a is required for proper cell cycle
progression in the fertilized mouse oocyte [57]. But in another
study (using cell lines distinct from A375/HCT116 cells), the
contrary is suggested: from nevus to metastatic melanoma CK1a
protein levels are increasingly down-regulated and are associated
with invasive tumour progression via alterations in b-catenin
stability [58]. Similar conclusions were made in colorectal/
intestine models using mice that showed extensive invasiveness
following the loss of CK1a therefore suggesting it functions as a
tumour suppressor [18].
Additionally, expression levels of both splice variants of CK1a
and their ratios greatly fluctuate from one cancer cell line to
another as it is for CK1d protein levels (data not shown), which
underlie the importance to study their transcriptional, translational
and post-translational regulation that will give a clue into their
different roles. Previous studies have shown differences in
properties between these two transcript variants in terms of
activity, localisation and stability [8,9,46,47] but have not
evaluated their distinct roles. The mechanism of substrate
specificity is only beginning to be investigated between CK1
isoforms, for example between d/e and a [55]. In our hands there
was a slight difference in the interaction between the two CK1a
isoforms and MDM2, and as a result we focused only on the
dominant CK1a isoform, sp2, which was also specifically modified
by ubiquitination and neddylation after peptide 35 transfection.
To conclude, our identification of a bioactive peptide motif in
the ‘‘base’’ of CK1a (peptide 35, Figure 7) as a key binding site for
MDM2 protein highlights a region involved in protein-protein
interactions on CK1a. The peptide derived from this region in
CK1a that competes CK1a from its interactor MDM2
(Figure 10B), can induce growth arrest/death of the cells. Indeed,
as the interest in CK1 as a potential therapeutic target is only now
being strongly documented, the next challenge will be the
generation of specific protein-protein interaction inhibitors such
as peptide 35 that will form the basis for a growing Biologics toolbox
that contrast with genetic depletion and active site-directed small
molecule inhibitor approaches. Further research would define
peptide 35 binding to MDM2, but also what implications
ubiquitin and neddylation post-translational modifications have
on CK1a functions and properties.
Materials and Methods
Cell Lines
All the experiments were performed with the A375 cell line
(obtained from Professor P. Smith, University of Cardiff, UK;
[59]), which is an adherent human amelanotic malignant
melanoma cell line, with the H1299 cell line (from the ATCC
American Type Culture Collection; distributor LGC standards,
Middlesec, UK), which is an adherent lung carcinoma cell line, or
with HCT116 wild type (wt) and p532/2 cell lines (obtained
from Dr B Vogelstein, Johns-Hopkins, University, USA; [60]),
which are adherent human colon carcinoma cell lines. Cell stocks
were maintained in DMEM, RPMI 1640 or Mc Coy’s 5A
respectively (Gibco, Invitrogen) supplemented with 10% foetal
bovine serum (Autogen Bioclear), at 37uC and 10% CO2 for A375
cell line or 5% for H1299 and HCT116 cell lines.
Transient Transfection of Small Interfering RNA (siRNA)
siRNA to CK1a gene was obtained from Dharmacon (siGEN-
OME SMARTpool against Human CSNK1A1 (NM_001892)).
siCONTROL non-targeting siRNA Pool#2 was used as a control
(siRNA control). HCT116 cells were transfected using Dharma-
FECT (Dharmacon) according to the manufacturer’s instructions.
The final concentration of siRNA used was 40nM and cells were
incubated for 48 to 96 hours. DharmaFECT (Mock) and DMEM
only controls (untreated) were included.
Cell Treatments and Fractionation
D4476 (Calbiochem) was transfected using Attractene (Qiagen)
into A375 cells as recommended by the supplier. Cells were
treated with 40 mM of D4476 (final concentration) for 72 hours.
Mock transfected/DMSO solvent control was included. DMSO
was purchased from Sigma. Subcellular fractions of A375 cells
treated with D4476 were prepared with ProteoExtract kit
(Calbiochem) according to the manufacturer’s instructions. Pro-
teins from each fraction (10 mg, quantified by Bradford) were
subjected to Western Blotting. A Coomassie blue gel was also run
in parallel.
Urea Lysis and Western Blotting
Cells were harvested and lysed in urea buffer as described
previously [16]. Proteins (20 mg lysate, determined by Bradford)
were prepared in 46 SDS sample buffer (SB) containing 0.2 M
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dithiothreitol (SDS/DTT SB) and were finally resolved by
denaturing polyacrylamide gel electrophoresis and Western
blotting as previously described [16]. Primary antibodies are listed
in Table 2 and were used with the appropriate horseradish
peroxidise (HRP)-conjugated secondary antibody (rabbit anti-
mouse and swine anti-rabbit, DAKO; donkey anti-goat, Santa
Cruz Biotechnology).
In vivo Co-immunoprecipitation
A375 cells were harvested, lysed in co-immunoprecipitation (co-
IP) buffer and immunoprecipitation was performed as described
previously [16]. Briefly, lysates were precleared with Protein G
Sepharose (GE Healthcare) and then incubated with the indicated
MDM2 primary antibodies or CK1a antibody (Table 2). A no
antibody negative control was included. Protein G Sepharose was
then added to the pre-cleared samples. Supernatant (flow-through)
was collected and beads were washed several times with co-IP
buffer. After addition of SDS/DTT SB, samples were boiled and
eluates were collected. Samples were analysed by Western
Blotting. In additional experiments, 4 mg of pCMV wild type
MDM2 [31] or equivalent empty plasmid were transfected 24
hours prior to harvesting the cells.
Cloning and Expression of CK1a for in vivo Pull-down
CK1a transcript variant 2 was amplified by PCR from cDNA
obtained by reverse transcription of QPCR Human Reference
total RNA (Stratagene) using the following primers:
GCACTTCGGGATCCCATGGCGAGTAGCAGCGGCTCC
(forward) and GACGTATCGTCGATATCTTAGAAACCTTT-
CATGTTAC (reverse). CK1a transcript variant 1 was amplified by
PCR with the above primers from pCMV6-AC-GFP CK1a splice
variant 1 (Origene). CK1a ORFs were cloned in frame with an N-
terminal One-STrEP-TAG into pEXPR-IBA-105 (IBA BioTAG-
nology) using BamHI and EcoRV restriction enzymes. A375 cells
were transfected with 4 mg of the corresponding plasmid DNA,
using Attractene as described in the manufacturer’s handbook. An
empty vector only control was included. Cells were lysed in 0.2%
Triton lysis buffer (50 mM HEPES (pH 7.5), 0.2% (v/v) Triton X-
100, 150 mM NaCl, 10 mM NaF, 2 mM DTT, 0.1 mM
EDTA,1XcOmplete Mini protease inhibitor cocktail (Roche)) 24
hours post transfection. Three mg of lysate was added to 80 mL
(50% slurry) strep-Tactin MacroPrep (IBA) pre-washed in buffer
W (100 mM Tris (pH 8.0), 150 mM NaCl, 1 mM EDTA, 1 mM
benzamidine) and incubated for 1 hour at 4uC with gentle
rotation. The resin was pelleted by centrifuging at 1000 g for
5 min at 4uC, and then washed several times with buffer W.
OneSTrEP-proteins were eluted by the addition of 80 mL of SDS/
DTT SB at 85uC for 5 min. Lysates (40 mg) and eluates (20 mL)
were resolved by Western blotting.
Cloning and Expression of CK1a for in vitro Studies
CK1a transcript variant 2 and 1 cDNAs were amplified by PCR
from pEXPR-IBA-105 described above, using the following
primers: GCACTTCGCATATGCATGGCGAGTAG-
CAGCGGCTCC (forward) and GACGTATCGTCCTCGAGT-
TAGAAACCTTTCATGTTAC (reverse). CK1a ORFs were
cloned in frame with an N-terminal glutathione S-transferase
(GST) tag into pGEX-6P-1 (GE Healthcare) using NdeI and XhoI
restriction enzymes. BL21(DE3) competent E. coli cells were
transformed with the above plasmids and expression of CK1a
transcript variants was induced at 30uC for 3 hours with 1 mM
IPTG at an optical density of 0.5 at 600 nM. Afterwards, cells
were pelleted at 6000 g for 20 min at 4uC and cell pellets were
resuspended in lysis buffer (20 mM Tris (pH8), 150 mM NaCl,
0.1% (v/v) NP-40, 1 mg/mL lysozyme, 2 mM DTT, 16protease
inhibitor cocktail). Following incubation on ice, cells were snap-
frozen then quickly thawed and this freeze-thaw cycle was
repeated. Cells were then disrupted using SHM2 Homogeniser
(Stuart) and finally samples were centrifuged at 16000 g for
15 min at 4uC. Supernatants were combined with 50% slurry
Glutathione Sepharose 4B beads (Amersham GE) prewashed in
buffer A (20 mM Tris (pH8), 150 mM NaCl, 0.1% (v/v) NP-40,
2 mM DTT, 2 mM benzamidine) and incubated for 1 hour at
4uC with gentle rotation. Suspensions were mounted on 5 mL
disposable MoBiCol columns (MoBiTec) fitted with 35 mm pore-
size lower filters and Luer-lock caps and emptied by gravity. After
washes in buffer A, further washes were performed in buffer B
(buffer A supplemented with 10 mM MgCl2 and 5 mM ATP)
Table 2. Different primary antibodies used for Western blotting, ELISA and co-immunoprecipitation.
Target protein Clone Primary antibody type Supplier
b-actin AC-15 Mouse monoclonal Sigma (#A5441)
CK1a C-19 Goat polyclonal Santa Cruz Biotechnology (#SC-6477)
CK1d – Rabbit polyclonal Bethyl Laboratories (#A302-136A)
CK1e – Mouse monoclonal BD Transduction Laboratories (#610445)
MDM2{ 2A10 Mouse monoclonal From Borek Vojtesek, Brno, Czech Republic*
MDM2{ 4B2 Mouse monoclonal From Borek Vojtesek, Brno, Czech Republic*
MDM2 2A9 Mouse monoclonal From Borek Vojtesek, Brno, Czech Republic*
MDM2 3G5 Mouse monoclonal From Borek Vojtesek, Brno, Czech Republic*
MDM2 SMP14 Mouse monoclonal From Borek Vojtesek, Brno, Czech Republic*
p21 EA10 Mouse monoclonal Calbiochem (#OP64)
p53 DO1 Mouse monoclonal From Borek Vojtesek, Brno, Czech Republic*
HP1a 15.19s2 Mouse monoclonal Millipore (#05-689)
HSP70 C92F3A-5 Mouse monoclonal Stressgen (#SPA-810)
*Dept. of Experimental Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
{Unless specified otherwise, a mix of both antibodies was used for Western Blotting; 2A10 was used in ELISAs.
doi:10.1371/journal.pone.0043391.t002
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then in buffer A. Recombinant proteins were eluted by incubation
in elution buffer (100 mM Tris (pH 8), 120 mM NaCl, 40 mM
glutathione) for 30 min at 4uC with rotation. Finally, the buffer
was exchanged using Zeba Desalt Spin columns (Pierce) according
the manufacturer’s instructions into kinase buffer (50 mM Tris
(pH 8), 150 mM NaCl, 0.5 mM EDTA, 0.02% Triton X-100,
2 mM DTT).
Expression and Purification of MDM2
MDM2 was expressed as GST-tagged protein using pGEX-6P-
1 and GST was then cleaved off using PreScission protease (GE
Healthcare) as described previously [61].
Direct Protein-binding ELISA
Proteins used for direct protein-binding assays were GST-
cleaved MDM2 and GST-tagged recombinant CK1a transcript
variants 1 and 2. ELISA 96-well plates (Costar) were coated with
either 20 ng of CK1a or 50 ng of MDM2 in coating buffer (0.1 M
NaHCO3 pH 8.6) by incubating overnight at 4uC. GST alone
and/or coating buffer only controls were included. After washing
with PBS-T (PBS supplemented with 0.1% Tween-20), non-
specific binding was blocked by incubation in blocking buffer (3%
BSA in 16 PBS) for 1 hour at room temperature. A titration of
MDM2 or CK1a respectively in blocking buffer was then added
and the plate was incubated for 1hour at room temperature.
Following further washes, the plate was incubated with primary
antibody specific to MDM2 or CK1a (Table 2) for 1 hour at room
temperature. After washing, the appropriate HRP-conjugated
secondary antibody was added and the plate was incubated for 1
hour at room temperature. After final washing, binding was
measured by enhanced chemiluminescence (ECL). The lumines-
cence produced was immediately detected with a Fluoroskan
Ascent FL luminometer and Ascent software version 2.4.1
(Labsystems). BSA background was subtracted to normalise values.
Peptide Affinity Chromatography-based Pull-down
A375 untreated cells were lysed in 0.1% Triton lysis buffer. The
technique has been described previously [62]. Lysate was pre-
cleared using Sepharose CL 4B beads prewashed in buffer W for 1
hour at 4uC with gentle shaking. Beads were centrifuged at 500 g
for 3 min at 4uC and supernatant was collected and assayed for
protein concentration. In parallel, peptide affinity columns were
prepared using MoBiCol column jackets: 100 ml of 50% slurry
streptavidin-agarose beads (Invitrogen) was added to each empty
column and washed with buffer W. Ten mg of each of the CK1a
biotinylated peptides in PBS was added to the individual columns
and incubated for 1 hour at room temperature on a rotating table.
A DMSO control was included. After several washes with buffer
W, 0.5 mg of pre-cleared lysate was added to the peptide column
and incubated with the resin for 1 hour at room temperature on a
rotating table. Following further washes with buffer W supple-
mented with 0.2% Triton X-100 (v/v) and then buffer W, the
beads were transferred from the columns to microfuge tubes which
were then centrifuged at 500 g for 3 min at room temperature.
Bound proteins were eluted by boiling in 50 ml SDS/DTT SB
(100 mM DTT) for 5 min at 85uC. Beads were pelleted by
centrifuging at 500 g for 3 min at room temperature, and the
eluates were analysed by Western blotting.
Peptide-based ELISA
Fifteen-mer biotinylated CK1a peptides (5-mer overlap at each
extremity, SGSG spacer) were purchased from Chiron Mimotopes
and dissolved at 5 mg/mL in DMSO. In peptide binding assays,
ELISA plates were adsorbed with streptavidin (AnaSpec) over-
night and washed with PBS-T, then biotinylated peptides diluted
in water (1 mg per well) were added for 1 hour followed by
blocking with 3% BSA in 16PBS. Twenty ng of MDM2 diluted
in blocking buffer were then added to the plate and incubated for a
further 1 hour. Blocking buffer and DMSO only controls were
included. After further washes, wells were incubated with MDM2
primary antibody and then the appropriate horseradish peroxidase
antibody (Table 2) for 1 hour each at room temperature followed
by further washing and ECL addition and the luminescence
produced was measured. BSA background was subtracted to
normalise values.
Competition ELISA
The assay was carried out in a similar manner to direct protein-
binding ELISA except that a fixed amount of MDM2 was pre-
incubated 20 min at room temperature with a titration of peptide/
drug (except for CK1a ligand Pyrvinium) in ELISA buffer
(25 mM Hepes (pH 7.5), 50 mM KCl, 10 mM MgCl2) before
addition to GST-CK1a transcript variant 2 (20 ng/well) coated on
the plate. The p53 BOX-I and BOX-V sequences are
PPLSQETFSDLWKLLP and RNSFEVRVCACGRD respective-
ly. The CK1a stimulator molecule Pyrvinium was obtained from
Ascent Scientific. BSA background was subtracted to normalise
values.
Peptide Competition Ubiquitination Assay
The in vitro assay was carried out as previously described [31]
except using untagged p53 purified from insect cell lines as
substrate (kindly donated by Jennifer A. Fraser, purified as
previously published [63]) and reactions were started with
MDM2 (20 ng/mL) pre-incubated for 10 min at room tempera-
ture with CK1a peptides (50 mM). A DMSO control and a no
MDM2 control (p53+ peptide 2 only) were included. Samples
were then incubated at 30uC for 15 min and reactions were
stopped by addition of SDS/DTT SB. p53 ubiquitination was
analyzed immunochemically by running 4%–12% NuPAGE gels
in a MOPS buffer system (Invitrogen) followed by Western
blotting with an anti-p53 antibody.
Cloning of CK1a for Expression in Reticulocyte Lysate
CK1a transcript variants 1 and 2 were amplified by PCR from
pEXPR-IBA-105 containing CK1a (see above) using the following
primers: GCACTTCGGGATCCGCCACCATGGCGAGTAG-
CAGC (forward) and GACGTATCGTCCTCGAGTTA-
GAAACCTTTCATGTTAC (reverse). CK1a ORFs were then
cloned into pcDNA3.1+ (Invitrogen) using BamHI and XhoI
restriction enzymes. CK1a transcript variants were then expressed
using the TNT T7 Quick coupled Transcription/Translation kit
(Promega) according to the manufacturer’s instructions. Five mg of
the reaction was analysed by Western blotting alongside 30 mg of
untreated A375 lysate.
Peptide Transfection into Cells
Selected CK1a peptide (0.5 to 50 mM) was transfected into
A375 or HCT116 cells using Nucleofectin reagent and Nucleo-
fector II device following the manufacturer’s protocol (Amaxa Cell
Line Nucleofector Kit V (LONZA)). After 18 hours, cells were
harvested, lysed and protein levels were assessed by Western
blotting. A DMSO control and/or control peptide were included.
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Cloning and Expression of FLAG-tagged CK1a Peptides
The DNA sequence encoding peptide 35 with an N-terminal
SGSG spacer (GAATTCTTCAGGATCAGGAGATTACATG-
TATCTGAGGCAGCTATTCCGCATTCTTTTCAGGACC-
TAAGGATCC for peptide 35) was ligated into the 59 EcoRI and
39 BamH1 sites of p3xFLAG-Myc-CMV-26 resulting in the
removal of the Myc C-terminal tag. Therefore the FLAG-Myc
empty plasmid was used as a peptide control.
In vivo Purification of His-tagged Ubiquitin/NEDD8
Conjugates
H1299 cells were transfected with equivalent amounts (0.5 mg)
of STReP-tagged CK1a splice variant (sp) 1 or 2, FLAG-tagged
peptide 35 and His-Ubiquitin or His-Nedd8, using Attractene as
described in the manufacturer’s handbook. Eighteen hours after
transfection cells were treated with 50 mM MG132 (Calbiochem)
for 4 hours. They were washed with PBS and scraped in 1 ml of
PBS. Twenty percent of cell suspension was lysed in urea buffer.
His-ubiquitin/nedd conjugates were purified as previously de-
scribed [64] and analyzed by 4%–12% NuPAGE/immunoblots
with an anti-CK1a antibody.
Cell Cycle Analysis and Cell Counting
Cells were harvested in the medium by scraping on ice. Cells
were then fixed, stained with propidium iodide and analysed by
FACS analysis as described before [16]. A cell aliquot was taken
first to count non-viable cells stained with Trypan Blue (Sigma) at
0.2% final concentration.
Supporting Information
Figure S1 Effects of CK1a depletion on the stability of
CK1d and e isoforms. A375 cells were transfected with control
siRNA (40 nM; lanes 3 & 7) or with CK1a-specific siRNA
(40 nM; lanes 4 & 8) for 48 hours (lanes 1–4) or 72 hours (lanes 5–
8). A Mock transfected control (lanes 2 & 6) and an untreated
control (DMEM only; lanes 1 & 5) were included. Cell lysates were
analysed by Western blotting with antibodies targeting the
indicated proteins.
(DOCX)
Figure S2 Effects of CK1 inhibition on p53 and CK1
isoforms subcellular protein levels. A375 cells were
transfected with 40 mM final concentration of the CK1 inhibitor
D4476 for 72 hours. Cells were then fractionated into four
subcellular compartments: cytosol, membranes and membrane
organelles, nucleic proteins, and cytoskeletal components. Cell
subcellular lysates were immunoblotted (Figure 1B) and quantifi-
cation of different protein levels in each fraction was assessed with
Scion Image software. To remove any loading or protein
concentration measurement inaccuracies, normalisation was
performed by quantifying total protein levels of each fraction on
a Coomassie blue gel (B) or the Ponceau-stained blot, then
applying the difference factor between each fraction type to the
Western blot protein quantification. The experiment was repeated
at least three times (after 48 and 72 hours with 20 and 40 mM of
D4476). Average p53 protein levels in each fraction before and
after treatment are displayed in subfigure (C) which also shows
standard deviations.
(DOCX)
Figure S3 Co-immunoprecipitation of CK1 isoforms
with MDM2 in A375 cells. (A) MDM2 was immunoprecipi-
tated from A375 cell lysate using the 2A10 monoclonal antibody.
Co-immunoprecipitation was performed and included no anti-
body control and no lysate control. The flow-through (FT) and the
eluate (E) for both controls and sample were analysed by Western
blotting with anti-CK1a, d and e antibodies. Immunoprecipitation
of MDM2 protein was checked with a 1:1 mix of 2A10 and 4B2
antibodies. (B) Quantification of co-immunoprecipited CK1a
splice variant 2 protein levels was assessed with Scion Image
software in three independent MDM2 co-immunoprecipitation
experiments.
(DOCX)
Figure S4 Detection of CK1a splice variants by CK1a
antibody. Untagged CK1a splice variants 1 and 2 were
expressed with an in vitro translation kit (IVT, lanes 2 and 3
respectively) and loaded alongside A375 lysate (lane 4); then
examined by Western blotting with an antibody against CK1a. An
empty control (pcDNA3.1) for in vitro translation was included
(lane 1). The three panels represent decreasing exposure time of
the same immunoblot. There is a noteworthy difference in the
amount of both splice variants in A375 cell lysate, CK1a sp2 being
about five fold more abundant than CK1a sp1 (lane 4). In a
similar manner, sp2 was twofold more abundant than sp1 through
expression with the in vitro kit (lane 2 vs. 3, right panel). This
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